MXPr (Methoxpropamine)
MXPr (methoxpropamine) is an arylcyclohexylamine dissociative and homologue of methoxetamine, differing by an N-propyl group. It is sold as a research chemical and reported to be less potent than MXE with a longer duration; human data are almost nonexistent.
01 Overview
MXPr is the N-propyl analogue in the MXE/MXiPr series, developed as MXE itself was banned. It is reported to produce MXE-like dissociation at somewhat higher doses and with a long duration, but essentially nothing is known about its pharmacokinetics or safety in humans.
All available information is anecdotal. Reported effects are typical dissociative ones; the main practical hazards are the long duration and the near-total absence of toxicological data.
02 Mechanism
NMDA-receptor antagonist analogous to methoxetamine, with possible serotonergic activity inferred from the MXE series.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 10–25 mg | Oral | |
| Common | 15–40 mg | Insufflated | |
| Common | 25–60 mg | Oral | Long duration; wait before redosing. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| DissociationMXE-like dissociation reported, at somewhat higher doses. | Anecdotal | ||
| Sedation and analgesiaTypical dissociative sedation and pain relief. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Prolonged dissociation and redosingLong duration invites redosing and extended dissociative states. | Moderate | Reported anecdotally | Anecdotal | |
| Unknown toxicityNear-total absence of toxicological data means the safety profile is unknown. | Moderate | Uncharacterised | Unconfirmed |